Novel MAML2 Fusions in Human Malignancy
We identified novel <i>MAML2</i> fusion partners, most of which likely represent passenger alterations, possibly arising from genomic instability or impaired p53 function. However, <i>ATXN3::MAML2</i> fusions, previously reported in a pre-cancerous pancreatic disease case, may represent a pathogenic alteration warranting further investigation.
Authors
- Takefumi Komiya (ORCID: https://orcid.org/0000-0002-6484-2210)
- Chao Huang (ORCID: https://orcid.org/0000-0001-5664-0937)
- Emmanuel S. Antonarakis (ORCID: https://orcid.org/0000-0003-0031-9655)
- Andrew Elliott (ORCID: https://orcid.org/0000-0001-8494-8031)
- Kieran Sweeney (ORCID: https://orcid.org/0000-0002-4136-755X)
- Anthony Crymes
- Matthew James Oberley (ORCID: https://orcid.org/0000-0001-6419-2513)
- Mark G. Evans (ORCID: https://orcid.org/0000-0001-9358-9843)
Institutions
- University of Southern California (US)
- University of Kansas Medical Center (US)
- University of Minnesota Medical Center (US)
- Caris Life Sciences (United States) (US)
- Minnesota Oncology (US)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-27
- DOI
- https://doi.org/10.3390/cancers17193146
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00